[go: up one dir, main page]

WO2005108993A3 - Diagnostic et therapeutique de maladies associees a la proteine kinase kinase kinase 6 activee par des mitogenes (map3k6) - Google Patents

Diagnostic et therapeutique de maladies associees a la proteine kinase kinase kinase 6 activee par des mitogenes (map3k6) Download PDF

Info

Publication number
WO2005108993A3
WO2005108993A3 PCT/EP2005/004553 EP2005004553W WO2005108993A3 WO 2005108993 A3 WO2005108993 A3 WO 2005108993A3 EP 2005004553 W EP2005004553 W EP 2005004553W WO 2005108993 A3 WO2005108993 A3 WO 2005108993A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
kinase
map3k6
compounds
mitogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/004553
Other languages
English (en)
Other versions
WO2005108993A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2005108993A2 publication Critical patent/WO2005108993A2/fr
Publication of WO2005108993A3 publication Critical patent/WO2005108993A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne une MAP3K6 humaine qui est associée aux maladies cardiovasculaires, aux infections, aux maladies dermatologiques, aux maladies endocrinologiques, aux maladies métaboliques, au cancer, aux maladies gastroentérologiques, à l'inflammation, aux maladies hématologiques, aux maladies musculosquelettiques, aux maladies neurologiques, aux maladies urologiques et aux maladies respiratoires. L'invention porte également sur des analyses qui permettent d'identifier des composés utilisés dans le traitement des maladies cardiovasculaires, des infections, des maladies dermatologiques, des maladies endocrinologiques, des maladies métaboliques, du cancer, des maladies gastroentérologiques, de l'inflammation, des maladies hématologiques, des maladies musculosquelettiques, des maladies neurologiques, des maladies urologiques et des maladies respiratoires. L'invention se rapporte également à des composés qui se lient à MAP3K6 et/ou activent ou inhibent l'activité de MAP3K6, et à des compositions pharmaceutiques renfermant lesdits composés.
PCT/EP2005/004553 2004-05-11 2005-04-28 Diagnostic et therapeutique de maladies associees a la proteine kinase kinase kinase 6 activee par des mitogenes (map3k6) Ceased WO2005108993A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011156.9 2004-05-11
EP04011156 2004-05-11

Publications (2)

Publication Number Publication Date
WO2005108993A2 WO2005108993A2 (fr) 2005-11-17
WO2005108993A3 true WO2005108993A3 (fr) 2006-06-15

Family

ID=34967468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004553 Ceased WO2005108993A2 (fr) 2004-05-11 2005-04-28 Diagnostic et therapeutique de maladies associees a la proteine kinase kinase kinase 6 activee par des mitogenes (map3k6)

Country Status (1)

Country Link
WO (1) WO2005108993A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035837A2 (fr) * 2001-10-23 2003-05-01 Sagres Discovery Nouvelles compositions et procedes relatifs au cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035837A2 (fr) * 2001-10-23 2003-05-01 Sagres Discovery Nouvelles compositions et procedes relatifs au cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAISER ROBERT A ET AL: "Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 9 APR 2004, vol. 279, no. 15, 9 April 2004 (2004-04-09), pages 15524 - 15530, XP002343816, ISSN: 0021-9258 *
OMURA TAKASHI ET AL: "Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. FEB 2004, vol. 24, no. 2, February 2004 (2004-02-01), pages 270 - 275, XP002343817, ISSN: 1524-4636 *
WANG X S ET AL: "MAPKKK6, a novel mitogen-activated protein kinase kinase kinase, that associates with MAPKKK5", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 253, no. 1, 9 December 1998 (1998-12-09), pages 33 - 37, XP002169311, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2005108993A2 (fr) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005031346A3 (fr) Produits diagnostiques et therapeutiques destines aux maladies liees au recepteur adipor1 (adipor1) couple a la proteine g
WO2005108993A3 (fr) Diagnostic et therapeutique de maladies associees a la proteine kinase kinase kinase 6 activee par des mitogenes (map3k6)
WO2005118833A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a une kinase a motif sterile-alpha et a motif de type glissiere a leucine (zak)
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2006010514A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005078117A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)
WO2005085466A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 2 associee a rho (rock2)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2004086052A3 (fr) Produits de diagnostic et de therapeutique pour des maladies liees au recepteur de l'adenosine a2b couple a la proteine g (adora2b)
WO2005114210A8 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005090994A3 (fr) Diagnostic et therapeutique pour des maladies associees a la proteine kinase, dependante de cgmp, type 1 (prkg1)
WO2006005462A3 (fr) Diagnostic et therapeutique de maladies associees a la tyrosine kinase wee1 (wee1)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005054866A3 (fr) Agents diagnostiques et therapeutiques utilises dans le traitement des maladies associees au canal potassique de domaine a deux pores (kcnk2)
WO2005040822A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 25 couple a la proteine g (gpr25)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2004106934A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees au recepteur 7 de 5-hydroxytryptamine (serotonine) (5-ht7)
WO2004106935A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005059558A3 (fr) Diagnostic et therapie de maladies associees au recepteur couple a la proteine g mc4 (mc4)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase